HEPATIC AMYLOIDOSIS

This adverse event was reported 19 times

HEPATIC AMYLOIDOSIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 TAFAMIDIS MEGLUMINE 2 0.0004
1 VUTRISIRAN 1 0.0003
2 SALINE NASAL SPRAY 1 0.0002
3 CYPROHEPTADINE HYDROCHLORIDE 1 0.0002
4 TERBINAFINE HYDROCHLORIDE TABLET 1 0.0001
5 TERBINAFINE HYDROCHLORIDE 1 0.0001
6 LUBIPROSTONE 1 0.0001
7 TAFAMIDIS 1 0.0001
8 SIROLIMUS 1 0.0001
9 IXAZOMIB 2 0.0001
See all drugs enriched for association with HEPATIC AMYLOIDOSIS